GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Strides Pharma Science Ltd (BOM:532531) » Definitions » Cyclically Adjusted Book per Share

Strides Pharma Science (BOM:532531) Cyclically Adjusted Book per Share : ₹345.65 (As of Sep. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Strides Pharma Science Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Strides Pharma Science's adjusted book value per share for the three months ended in Sep. 2024 was ₹247.005. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ₹345.65 for the trailing ten years ended in Sep. 2024.

During the past 12 months, Strides Pharma Science's average Cyclically Adjusted Book Growth Rate was -6.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-12-12), Strides Pharma Science's current stock price is ₹737.75. Strides Pharma Science's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 was ₹345.65. Strides Pharma Science's Cyclically Adjusted PB Ratio of today is 2.13.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Strides Pharma Science was 4.73. The lowest was 0.79. And the median was 1.13.


Strides Pharma Science Cyclically Adjusted Book per Share Historical Data

The historical data trend for Strides Pharma Science's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Strides Pharma Science Cyclically Adjusted Book per Share Chart

Strides Pharma Science Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 337.32 364.31 353.52

Strides Pharma Science Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 368.42 - 353.52 - 345.65

Competitive Comparison of Strides Pharma Science's Cyclically Adjusted Book per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Strides Pharma Science's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Strides Pharma Science's Cyclically Adjusted PB Ratio falls into.



Strides Pharma Science Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Strides Pharma Science's adjusted Book Value per Share data for the three months ended in Sep. 2024 was:

Adj_Book= Book Value per Share /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=247.005/157.8822*157.8822
=247.005

Current CPI (Sep. 2024) = 157.8822.

Strides Pharma Science Quarterly Data

Book Value per Share CPI Adj_Book
201412 0.000 96.780 0.000
201503 193.872 97.163 315.027
201506 0.000 99.841 0.000
201509 199.302 101.753 309.240
201512 0.000 102.901 0.000
201603 297.480 102.518 458.131
201606 0.000 105.961 0.000
201609 290.006 105.961 432.109
201612 0.000 105.196 0.000
201703 307.960 105.196 462.198
201706 0.000 107.109 0.000
201709 303.658 109.021 439.750
201712 0.000 109.404 0.000
201803 275.269 109.786 395.860
201806 0.000 111.317 0.000
201809 264.059 115.142 362.077
201812 0.000 115.142 0.000
201903 295.781 118.202 395.074
201906 0.000 120.880 0.000
201909 290.108 123.175 371.852
201912 0.000 126.235 0.000
202003 282.186 124.705 357.260
202006 0.000 127.000 0.000
202009 300.005 130.118 364.019
202012 0.000 130.889 0.000
202103 309.615 131.771 370.968
202106 0.000 134.084 0.000
202109 267.950 135.847 311.413
202112 0.000 138.161 0.000
202203 262.749 138.822 298.825
202206 0.000 142.347 0.000
202209 258.209 144.661 281.808
202212 0.000 145.763 0.000
202303 244.982 146.865 263.360
202306 0.000 150.280 0.000
202309 227.328 151.492 236.917
202312 0.000 152.924 0.000
202403 231.292 153.035 238.619
202406 0.000 155.789 0.000
202409 247.005 157.882 247.005

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Strides Pharma Science  (BOM:532531) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Strides Pharma Science's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=737.75/345.65
=2.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Strides Pharma Science was 4.73. The lowest was 0.79. And the median was 1.13.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Strides Pharma Science Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Strides Pharma Science's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Strides Pharma Science Business Description

Traded in Other Exchanges
Address
Strides House, Bannerghatta Road, Bilekahalli, Bengaluru, KA, IND, 560 076
Strides Pharma Science Ltd is a specialty and generic drug manufacturer. The company focuses on developing niche and complex pharmaceutical products across therapeutic segments for regulated and emerging markets. Strides' emerging-market plan focuses on branded generics for the treatment of chronic therapies. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. The company's reportable segment are; Pharmaceutical & Bio-pharmaceutical.

Strides Pharma Science Headlines

No Headlines